Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_3
1
17%
Ph phase_2
2
33%
Ph phase_1
1
17%
Ph phase_4
1
17%
Ph not_applicable
1
17%

Phase Distribution

1

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Other(2)

Detailed Status

Completed4
unknown2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (16.7%)
Phase 22 (33.3%)
Phase 31 (16.7%)
Phase 41 (16.7%)
N/A1 (16.7%)

Trials by Status

unknown233%
completed467%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza

NCT02469298
unknownnot_applicable

Evaluate the Safety and Efficacy of Xiyanping in Pediatric Participants With Severe Influenza-Like Symptoms

NCT03947411
completedphase_3

A Multinational Phase III Study of CS-8958 (MARVEL)

NCT00803595
unknownphase_4

Banlangen Granules Anti-seasonal Influenza Study

NCT02232945
completedphase_2

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

NCT00979251
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02469298Phase 2

Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza

Completed
NCT03947411Not Applicable

Evaluate the Safety and Efficacy of Xiyanping in Pediatric Participants With Severe Influenza-Like Symptoms

Unknown
NCT00803595Phase 3

A Multinational Phase III Study of CS-8958 (MARVEL)

Completed
NCT02232945Phase 4

Banlangen Granules Anti-seasonal Influenza Study

Unknown
NCT00979251Phase 2

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

Completed
NCT00416962Phase 1

Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6